CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $3,241,000 | -57.2% | 42,766 | -36.8% | 0.32% | -60.5% |
| Q3 2021 | $7,574,000 | -30.7% | 67,666 | +0.2% | 0.81% | -28.5% |
| Q2 2021 | $10,932,000 | +126.4% | 67,527 | +70.4% | 1.13% | +111.4% |
| Q1 2021 | $4,829,000 | -10.4% | 39,628 | +12.6% | 0.54% | -18.4% |
| Q4 2020 | $5,389,000 | +127.6% | 35,194 | +24.3% | 0.66% | +83.5% |
| Q3 2020 | $2,368,000 | +28.6% | 28,308 | +13.0% | 0.36% | +1.1% |
| Q2 2020 | $1,841,000 | +206.8% | 25,046 | +77.0% | 0.35% | +164.2% |
| Q1 2020 | $600,000 | -2.6% | 14,149 | +40.0% | 0.13% | +14.5% |
| Q4 2019 | $616,000 | +48.1% | 10,109 | -0.5% | 0.12% | +51.9% |
| Q3 2019 | $416,000 | -13.0% | 10,158 | 0.0% | 0.08% | -22.2% |
| Q2 2019 | $478,000 | +31.7% | 10,158 | 0.0% | 0.10% | +25.3% |
| Q1 2019 | $363,000 | +25.2% | 10,158 | 0.0% | 0.08% | +12.9% |
| Q4 2018 | $290,000 | -35.4% | 10,158 | +0.4% | 0.07% | -23.9% |
| Q3 2018 | $449,000 | – | 10,115 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |